Preclinical programs at TD2 run on syngeneic, orthotopic, patient-derived xenograft, cell line derived xenograft, humanized immune checkpoint inhibitor, and diet-induced obesity tumor models, alongside adoptive cell therapy studies. Bioanalytical support covers DMPK and ADME work, metabolomics and proteomics, in vivo optical imaging, and flow cytometry panels that carry through from preclinical into clinical phases. Regulatory offerings include gap analysis and roadmap development, scientific and medical writing, expert panel discussions, and submission and specialty filings. On the clinical side, teams handle protocol design, patient identification and site engagement, site monitoring, biostatistics, data management, pharmacovigilance, eTMF management, and medical monitoring. Focus areas span radiopharmaceuticals, hematologic malignancies, antibody-drug conjugates, small molecules, and cancer vaccines, with a modality history that also covers targeted therapies and immuno-oncology.
TD2
Therapeutic Discovery and Development (TD2) is an oncology-focused contract research organization (CRO) that provides integrated preclinical, regulatory, and clinical trial services. By leveraging unique tumor models, deep oncology insights, and accelerated regulatory pathways, TD2 assists biotech sponsors in rapidly moving promising cancer therapies from the bench to clinical proof-of-concept.
